The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2020

Filed:

Aug. 23, 2017
Applicant:

Shire Human Genetic Therapies, Inc., Lexington, MA (US);

Inventors:

Nazila Salamat-Miller, Arlington, MA (US);

Katherine Taylor, Arlington, MA (US);

Paul Campolieto, Charlottesville, VA (US);

Zahra Shahrokh, Weston, MA (US);

Jing Pan, Boxborough, MA (US);

Lawrence Charnas, Natick, MA (US);

Teresa Leah Wright, Lexington, MA (US);

Pericles Calias, Melrose, MA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/47 (2006.01); A61K 35/76 (2015.01); A61K 35/761 (2015.01); A61K 9/19 (2006.01); C12N 9/24 (2006.01); A61K 9/00 (2006.01); A61K 38/46 (2006.01); C07K 14/65 (2006.01); C12N 9/42 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01);
U.S. Cl.
CPC ...
A61K 38/47 (2013.01); A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 35/76 (2013.01); A61K 35/761 (2013.01); A61K 38/46 (2013.01); A61K 38/465 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); C07K 14/65 (2013.01); C12N 9/2402 (2013.01); C12N 9/2437 (2013.01); C12Y 301/06008 (2013.01); C12Y 301/06013 (2013.01); C12Y 302/0105 (2013.01); C12Y 302/01045 (2013.01); C12Y 302/01046 (2013.01); C12Y 310/01001 (2013.01);
Abstract

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.


Find Patent Forward Citations

Loading…